Gilead Stock News

Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.

Gilead Sciences (NASDAQ: GILD ) stock is on the move Thursday following FDA approval for its Veklury Covid-19 treatment. This saw the FDA approve the company's supplemental new drug application (sNDA)

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Healthcare Co

Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%,

Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.

Gilead Sciences, Inc. (NASDAQ:GILD) said the Food and Drug Administration (FDA) has put a clinical hold on its studies evaluating its investigation anti-CD47 immunotherapy magrolimab for acute myeloid

Gilead Sciences said on Monday the U.S. Food and Drug Administration had placed a partial clinical hold on initiating new patients in the U.S. studies for drug to treat a type of blood cancer.

Gilead Sciences Inc. GILD, -0.81% said Monday that the U.S. Food and Drug Administration has put a partial clinical hold on U.S. studies evaluating a treatment for acute myeloid leukemia. Screening an

Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.

Gilead Sciences said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases.

Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus' spread. But medical innovations and technological breakthroughs are rapidly transforming the health

Despite their falling stock prices, both of these companies have solid prospects. Pfizer has been busy making deals -- something that is already paying off.

Gilead Sciences has experienced a boom-bust-recovery cycle, with its fortunes changing after acquiring Pharmasset and obtaining a cure for HCV. Revenues have been stagnant for nearly a decade, with th

On August 6, 2023, Gilead Sciences Inc ( GILD , Financial) experienced a day's change of 4.17%, with the stock price at $78.68. The company's Earnings Per Share (EPS) stood at 4.35.

Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.